

SUPPLEMENTAL LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>					ATTY. DOCKET NO. 8449-128-999	APPLICATION NO. 09/668,724
					APPLICANT Srivastava, Pramod K.	
					FILING DATE September 22, 2000	GROUP 1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
CY	DN	WO 00/54801	09/21/00	PCT				
CY	DO	WO 02/07755	1/3/2002	PCT				
CY	DP	WO 94/14471	07/07/1994	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

CY	DQ	Agostoni et al., 1994, "Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator." <i>Circulation</i> . 90(6):2666-70.
CY	DR	Bednar et al., 1997, "Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke." <i>J. Neurosurg.</i> 86(1):139-42.
CY	DS	Collen et al., 1989, "Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent." <i>Drugs</i> . 38(3):346-88.
CY	DT	Katsutani et al., 1992, "Immunogenic properties of structurally modified human tissue plasminogen activators in chimpanzees and mice." <i>Fundam Appl Toxicol</i> . 19(4):555-62.
CY	DU	Opekun et al., 1999, "Novel therapies for Helicobacter pylori infection." <i>Aliment Pharmacol Ther</i> . 13(1):35-41.
CY	DV	Reed et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." <i>Thromb Haemost</i> . 64(2):276-80.
CY	DW	Zimecki et al., 1999, "Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells." <i>Arch Immunol Ther Exp (Warsz)</i> . 47(2):113-8.

EXAMINER *Chasey L HY*

DATE CONSIDERED

2-20-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conference and not considered. Include copy of this form with next communication to applicant.